NRC.F Neuronetics Inc

Healthcare Biotechnology Frankfurt Exchange
1.25 EUR
Close of Nov 13, 2026
0.9780 2.74
Market cap
EUR 97.2M
P/E
-
P/B
6.84x
ROE
-113.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NRC.F undervalued?

Graham number

The Graham number of Neuronetics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neuronetics Inc fundamental analysis

No fundamental analysis for Neuronetics Inc yet.

Neuronetics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neuronetics Inc

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to …

Full company profile